Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

857
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
857
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.3K
Protein Networks02:26

Protein Networks

4.0K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generative AI for controllable protein sequence design: A survey.

npj drug discovery·2026
Same authorSame journal

Unified heterogeneity-aware benchmark of drug synergy prediction: a cross-study analysis of traditional machine learning and graph deep learning models.

Journal of cheminformatics·2026
Same author

Revisiting ADMET prediction reliability under real-world challenges in the foundation model era.

Journal of cheminformatics·2026
Same author

Learning the PTM code through a coarse-to-fine mechanism-aware framework.

Nature communications·2026
Same author

A scalable and quantum-accurate foundation model for biomolecular force fields via linearly tensorized quadrangle attention.

Nature communications·2026
Same author

LamNet: an alchemical-path-aware graph neural network to accelerate binding free energy calculations for drug discovery and beyond.

National science review·2026
Same journal

Multimodal feature fusion for molecular property classification.

Journal of cheminformatics·2026
Same journal

P2MAT: A machine learning (ML) driven software for Property Prediction of MATerial.

Journal of cheminformatics·2026
Same journal

Computational design of low-volatility lubricants for space using interpretable machine learning.

Journal of cheminformatics·2026
Same journal

OpenStats: how to combine statistics and research data management (RDM) to leverage efficient scientific data analysis by guided statistics.

Journal of cheminformatics·2026
Same journal

Count your bits: fingerprint benchmarking to assess broad chemical space representation.

Journal of cheminformatics·2026
See all related articles

Related Experiment Video

Updated: Aug 17, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

246

ReMODE: a deep learning-based web server for target-specific drug design.

Mingyang Wang1,2, Jike Wang1,2, Gaoqi Weng1,2

  • 1Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences and Cancer Center, Zhejiang University, Hangzhou, 310058, Zhejiang, People's Republic of China.

Journal of Cheminformatics
|December 12, 2022
PubMed
Summary
This summary is machine-generated.

Receptor-based Molecular Design (ReMODE) is a new web server that uses deep learning for target-specific drug design. It simplifies complex processes, enabling researchers to create custom drug candidates more efficiently.

Keywords:
Adversarial autoencodersArtificial intelligenceDe novo drug designDeep learningMolecular generationTransfer learning

More Related Videos

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.8K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

Related Experiment Videos

Last Updated: Aug 17, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

246
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.8K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.1K

Area of Science:

  • Computational chemistry and cheminformatics.
  • Artificial intelligence in drug discovery.
  • Molecular modeling and design.

Background:

  • Deep learning (DL) and machine learning (ML) have advanced basic biology and drug discovery.
  • DL-based generative models show promise for de novo drug design.
  • Challenges remain in applying DL to drug design due to data, processing, and usability issues.

Purpose of the Study:

  • To present ReMODE (Receptor-based MOlecular DEsign), a novel web server for target-specific ligand design using DL.
  • To provide a user-friendly platform integrating customizable drug design functionalities.
  • To facilitate the application of DL techniques in drug discovery research.

Main Methods:

  • Development of a web server employing a DL algorithm for molecular design.
  • Integration of functional modules for customizable drug design tasks.
  • Implementation of features for optimizing drug-likeness, synthetic accessibility, and physicochemical properties.
  • Inclusion of fragment-based design starting points and optimization of pharmacophore matching and docking.

Main Results:

  • ReMODE enables the construction of target-specific drug design tasks based on user-selected protein targets.
  • The server supports optimization of molecular properties and scaffold-based design.
  • Pharmacophore matching and docking conformation optimization are integrated functionalities.
  • The platform aims to streamline and enhance the de novo drug design process.

Conclusions:

  • The ReMODE web server offers a powerful and accessible tool for researchers in drug discovery.
  • It addresses current limitations in applying DL to drug design by providing a user-friendly interface and integrated functionalities.
  • ReMODE is expected to accelerate the identification and optimization of novel drug candidates.